Drug Search Results
More Filters [+]


Alternative Names: peg-5000, peg5000, peg 5000
Latest Update: 2024-05-14
Latest Update Note: PubMed Publication

Product Description

Pegylated Human Recombinant Arginase for Liver Cancer (Sourced from: https://clinicaltrials.gov/ct2/history/NCT00988195?V_2=View)

Mechanisms of Action: Unknown

Novel Mechanism: No

Modality: Coagulation Factor

Route of Administration: Intravenous

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Bio-Cancer Treatment International Limited
Company Location:
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for PEG-5000

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases



Trial Status


Primary Completion Date

Probability of Success

Recent News Events